
price close busi march
global leader anim health diagnost
instrument lab test softwar sell direct
global sale rep
diagnost tool
despit nois reiter buy pt
recent privileg host cfo brian mckeon sr director
financ head ir john ravi meet reinforc convict
remain outstand compani rel reason expect set
stage anoth good year sharehold believ investor concern
combin zoetis-abaxi overblown believ realist opportun
exceed all-tim high not-too-dist futur reiter buy
rais pt street-high
durabl resili model laser focus reinforc busi model
extrem durabl given revenu recur ask
possibl indic laser focus expand lead anim health
diagnost softwar look diversifi
see synergi pharma contrari zoeti perspect
indic see lot synergi anim health diagnost
therapeut fact therapeut divis ridg pharmaceut
sold year ago lack synergi pharma diagnost
indic call point dx typic practic owner treatment
call point often doctor within practic one zoeti lead drug
apoquel often prescrib itchi dog argu diagnost test
diagnos itch limit util mani zoeti treatment use
companion anim rather product anim
model see know fast work pipelin
model rev investor know invest
industri sell-sid estim incorpor valu new revenu
ep associ product yet announc mum product launch
 team hard work confid see futur innov perhap in-
clinic molecular diagnost higher-throughput next-gen chemistri hematolog new
test on-a-slid possibl sequencing-bas test hit beyond
clinic patient visit hold end-us demand remain strong despit
rise on-line channel call indic sampl custom
patient visit deceler recent peak
though clinic patient visit grew
note rise on-line provid like vet first choic petiq pet owner
sourc medic food outsid tradit vet clinic see threat
clinic patient visit dx revenu stream reassur investor rise
prevent care clinic rise millenni -age pet owner vet new
test like sdma sedivu major uptick util dx test ou mark
target ask initi anim dx revenue spend target
indic target sought help
investor better understand compani grow salesforc
spend help investor pushback stock valuat ep
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
focus reiter buy rais pt
recent privileg host cfo brian mckeon sr director
financ head ir john ravi meet reinforc convict
outstand compani rel reason expect believ
pois anoth good year sharehold believ investor concern
combin zoetis-abaxi overblown particularli believ
realist opportun exceed all-tim high not-too-dist
futur reiter buy rate rais price target street-high
use multipl unchang adj ep estim
y/i
durabl resili busi model laser focus expand core leadership
reinforc busi model extrem durabl given
revenu recur aid elit level custom retent
ask possibl indic laser focus expand
lead anim health diagnost softwar look diversifi
histor deploy much free cash back busi
 increas steadier buyer stock via share buyback
said made small acquisit typic strengthen softwar offer
occasion acquir distributor outsid us fortifi refer lab
offer indic futur acquisit would like continu small
size would like use toward enhanc technolog
see synergi pharma contrari zoeti view indic
see lot synergi anim health diagnost therapeut
fact oper therapeut divis ridg pharmaceut sold
year ago lack synergi pharma diagnost
indic call point dx typic practic owner treatment
call point often doctor within practic one zoeti lead drug apoquel
prescrib itchi dog argu diagnost test diagnos itch
limited/no util mani zoeti treatment order product
companion anim thu obviou us revenu synergi
zoeti abaxi bundl
see chang competit dynam zoeti acquir abaxi
commonli ask question investor meet
seen chang competit dynam sinc zoeti nyse
rate close acquisit abaxi juli deal announc
may zoeti indic call need integr abaxi onto
sap system global expect complet zoeti make
new hire ou particularli technic specialist folk need
train expect take quarter time hire
place see much traction zoeti indic expect full
diagnost specialti field forc place thu see like impact
though risk higher competit beyond zoeti
plan leverag broad portfolio product offer discount think
bundl loyalti program though earli inning us side
abaxiss busi zoeti integr abaxi us diagnost sale peopl
rep stay place didnt leav upon transit us sale
team zoeti indic start leverag legaci zoeti rep gener
lead legaci abaxi sale forc though also remain earli zoeti also
indic certain market ou re-evalu whether continu
use distributor begin go direct think reason conclud
buy unchang target price march
diagnost tool
combin zoetis-abaxi littl impact though
note element risk risk offer greater
bundl lower price pose degre risk believ zoeti
tremend amount learn ahead compet
domin global leader innov anim health diagnost
stand idl big commerci leadership posit remind
hold global sale forc count includ peopl
us peopl intern indic larg complet rais
ou presenc rep what doesnt fix
number mind futur compani expect continu expand
sale forc time particularli outsid us diagnost util rate
much lower us indic saw consum growth across
emerg market call brazil china robust grower china
idxx revenu though livestock/poultry/dairi lpd bigger
companion anim group china manag indic see
limit impact relat tariff china
model see know fast work pipelin
model revenu investor know invest
industri sell-sid estim incorpor valu
new revenu ep associ product yet announc mum new
product launch team hard work confid see futur
innov perhap in-clin molecular diagnost higher-throughput next-gen
chemistri hematolog new test on-a-slid possibl sequencing-bas test
could hit beyond
clinic patient visit hold vet demand remain strong despit
rise on-line channel call indic sampl custom
patient visit deceler recent peak
though clinic patient visit grew
note rise on-line provid like vet first choic petiq pet owner
sourc medic food outsid tradit vet clinic see
threat clinic patient visit dx revenu stream reassur investor
rise prevent care clinic rise millenni -age pet owner
vet new test like sdma sedivu major uptick util
dx test ou mark import revenu growth lever three notabl exampl fast-
petiq compani watch petiq nasdaq |not rate
provid vet servic vet-grad pet product includ prescript
medic over-the-count flea tick prevent health well
product dog cat petiq ipod juli
compani provid vet product sam club costco
bj addit pet specialti store petsmart petco pet suppli e-
commerc amazon chewi com etc retail pharmaci
pet owner avoid go veterinarian purchas
product januari acquir vip petcar provid vet well
prevent servic commun clinic well center
vaccin prescript medic well check employ
vet vip petcar websit ran search vip clinic within
mile offic boston search return clinic locat within pet
suppli tractor suppli compani retail petiq deliv
revenu y/i y/i organ includ
product sale servic revenu petiq provid revenu
guidanc least y/i adj ebitda least
buy unchang target price march
diagnost tool
y/i open least veterinari well clinic perhap
impress petiq indic target revenu billion plan
open well center locat
global distribut leader agre spin anim health
busi form separ compani merg fast-grow top
line compound-annual-growth-rate privately-held vet first choic form vet first corp
recent spun re-nam met ceo
shaw appreci substanti runway growth ahead
vet first choic portland found shaw father
david found vet first choic gener
revenu gener top-lin compound-annual-growth-rate nearli sinc
put pro-forma busi revenu well
sell directli vet clinic provid
prescript manag inventori manag appoint
manag help veterinari practic take back revenu clinic
lost on-line deep discount like help clinic find
gap care analyt platform drive practic revenu growth
activ recommend rx medic nutrit supplement over-the-counter
product understand nearli revenu come north
america believ henri schein anim health materi help
scale top line ou believ growth limit impact
sinc player diagnost least howev
own oper avimark improm practic
manag softwar compet covetru ceo
shaw state compani pursu opportun though expect
compani delev make much runway acquisit
think could possibl fold nasdaq buy
recal covetrus/henri schein exclus distributor us
still search larg ou partner
vetsourc privat similar vet first choic vetsourc
rel larg home deliveri pharmaci provid vetsourc establish
aim help veterinarian offer altern previous lose
in-clin pharma busi ultra-low-cost websit like
vetsourc negoti pharmaceut provid pet food compani
offer reason price ship directli pet owner home vetsourc
employ pharmacist pharmaci tech support need order
patient data patient visit data cite call
base recordkeep quarterli data disclos full
year averag full-year patient visit increas
respect specif custom practic
volum growth deceler said practic revenu hung
rel stronger patient visit data total practic revenu
increas respect four-year
time period view demonstr resili strong busi
model abl drive solid diagnost revenu growth custom
practic new product higher price even environ
patient visit might step due rise alternate/onlin channel
buy unchang target price march
diagnost tool
figur custom practic volum deceler deceler though vet clinic practic revenu still grow
role rise anim hospit consolid
mom pop vet clinic shift toward larger corporate-own clinic see
figur estim vet clinic
clinic us corpor ownership decad ago
said estim corpor clinic
revenu typic larger clinic tend test number
driver behind shift increas invest move anim health
privat equiti kkr exampl strateg buyer mar
inc huge privat held player anim health demonstr on-going interest
consolid anim hospit small clinic owner increasingli interest
join larger corporate-own entiti either cash retire/sel busi
benefit share greater economies-of-scal negoti vendor
among sever factor
alreadi well-posit larg corpor group though see
opportun take share leverag breadth product bundl
even said see opportun busi vca own mar
compet vca antech refer lab howev indic sinc
mar acquir vca antech year ago competit tension dissip sinc
antech lab rel small percentag mar overal larg pie revenu
believ help mar grow anim health hospit busi across
brand bluepearl banfield pet partner even vca hospit
remind year past abaxi announc five-year contract
banfield mar novemb contract novemb
understand suppli north banfield hospit time
announc vetscan hematolog analyz
may abaxi announc seven-year guarante three-year
annual renew suppli vca hospit time
announc may flagship vetscan chemistri analyz
rotor base understand larg contract come renew
may
buy unchang target price march
diagnost tool
figur anim clinic increasingli consolid primarili greater invest privat equiti come mar inc scale
buy unchang target price march
diagnost tool
figur anim clinic increasingli consolid primarili greater invest privat equiti come mar inc scale cont
rational unusu lengthi target investor meet
manag ask initi anim diagnost revenu spend
target billion billion indic target
sought help investor better understand compani continu make
invest grow sale forc spend rather acceler even
greater drop oper margin expans help investor
pushback stock valuat think rational sensibl
buy unchang target price march
diagnost tool
figur believ phase ii dx market featur steep improv standard care us ou
make posit impact see nice success
program launch america launch ou
annual revenu commit normal baselin level five- six-
year contract length believ model reson ou custom
often time bring chemistry/hematolog analyz first time
catalyst chemistri instrument still lot runway ahead
world-wide catalyst instal base stood roughli
anticip place catalyst analyz global believ
addit catalyst placement opportun ou includ vettest
upgrad greenfield placement competit win
opportun america reap benefit introduc sale
forc compens y/i grow grew us premium
instrument instal base grew top ou countri alon
repres nearli total intern in-hous opportun
ou market could grow much time commun
analyst day believ intern anim diagnost market
would current size util standard care
match us believ next year phase ii evolut
anim dx market global standard care essenti rise
execut formid global commerci team
estim ou companion anim dx market grow compound-annual-growth-rate
next year vs us believ addit
buy unchang target price march
diagnost tool
placement competit win opportun america
us suggest major runway ahead sustain solid global growth
driven fxn revenu cagr
latam canada apac europ respect look employ three
major commerci strategi drive consum growth ou
expand in-hous refer lab util market complet
diagnost solut market similar uk total dx market
target refer lab expans hope penetr in-hous
futur market similar germani total dx market opportun
priorit drive in-hous util expand product offer new
region market similar china market opportun
introduc econom valu sale metric ou sale
compens drove growth competitive/greenfield chemistri
placement y/i
long-term financi target look achiev us
consist updat august analyst day target five-year
revenu growth assum growth us
diagnost ou diagnost vet softwar
digit lpd next five year expect
deliv growth greenfield new product initi
assum sdma sedivu fecal antigen
upsid driven product pipelin
return-on-invest capit manag compens also point
outstand growth return invest capit year
compani came basi rate compar
respect think worth
point one hand criteria includ manag
compens addit key criteria includ organ growth oper margin
ep addit criteria includ qualit goal like launch new platform
product final meaning equiti compens award larger
annual bonu
buy unchang target price march
diagnost tool
figur reiter top-lin revenu compound-annual-growth-rate lt well long-term ep growth om expans
busi well appreci investor ask oper
water busi sinc busi similar busi companion anim
diagnost busi expect water busi rev
om grow top line next five year part base
growth overal market drink water revenu on-
premise/build use environment use round meet grow
demand test legionnair diseas manag indic peopl
infect legionnair diseas die addit solid high-singl
digit growth rate compani also hold custom retent rate
indic water busi distract manag indic water
busi worth anoth parti compani
ever divest water busi would detract lot profit
bottom line water busi anoth great busi oper margin
well corpor averag make good sens continu grow
invest histor water grown compound-annual-growth-rate howev
made chang includ commerci chang
acceler growth rate water segment sinc present
revenu compound-annual-growth-rate indic decis go direct countri
nearli direct water busi includ canada brazil norway sweden
finland ireland other one key reason acceler growth rate
rel prior year theme reson across busi
manag indic go direct gross margin volum increas
solid revenu growth rate nice think biggest benefit water
elit oper margin last year vs idxx
overal om estim market runway growth ahead
water busi present baselin admittedli
idxx overal revenu today acknowledg underappreci
compani water segment think nearli everi investor well
buy unchang target price march
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price march
diagnost tool
buy unchang target price march
diagnost tool
